Data Sheet 2_Tumor microenvironment-activated ferritin nanovector enables enhanced tumor d

A PDF document presents in vitro results for a novel ferritin-derived nanomedicine platform named The-05. The platform is designed to encapsulate and deliver KRASG12C inhibitors and degraders, activated by tumor microenvironment enzymes MMP-2 and MMP-9. The study, authored by Annalisa Pia Abbinantefina and shared on figshare in March 2026, provides proof-of-concept data for enhanced drug delivery in KRAS-mutated cancer cell models.

Use Cases

• Benchmarking nanocarrier drug encapsulation efficiency based on the described platform for KRASG12C inhibitors.
• Studying tumor microenvironment activation mechanisms based on the described MMP-2/MMP-9 sensitive design.
• Comparing in vitro therapeutic outcomes of nanocarrier-delivered drugs versus free drugs in KRAS-mutated NSCLC and PDAC models.

Strengths

• Data is shared under a permissive CC-BY-4.0 license.
• The description provides specific details on the nanoplatform's mechanism, payloads (Adagrasib, LC-2), and activation triggers (MMP-2, MMP-9).

Limitations

• The dataset is a 101.2 KB PDF; the underlying raw data, column definitions, and row counts are unavailable.
• The data scope is limited to in vitro proof-of-concept studies; in vivo or clinical validation is not included.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from laboratory research on the The-05 nanoplatform.

Freshness

Last updated 2026-03-17 13:08:12; freshness should be verified.